Phase 2 testing of Cyteir's lead cancer drug candidate later is slated to start later this year. The Series C round of funding includes crossover investors, whose involvement is a sign a biotech is preparing for an IPO.
Rather than manually entering their username and password every time they utilize a device, Imprivata Mobile Device Access lets clinicians tap their badge to a mobile device, then single sign-on into their applications.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Agile Therapeutics released "positive top-line phase 3 results" on Tuesday, but the market did not buy it. Its shares plummeted 74 percent, trumping the 68 percent drop inflicted upon Inotek Pharmaceuticals earlier in the day.